Drug details

Cinqair (reslizumab for intravenous infusion)

type of Monoclonal Antibodies, Anti-asthmatics

Cinqair (reslizumab) injection is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

The drug is often used to treat Asthma .

This drug may have the following side effects:

• mouth and throat pain.

The following drugs are related to Cinqair, either as a replacement or used together:

• Accolate (zafirlukast)
• Advair Diskus (fluticasone propionate)
• Advair HFA (fluticasone propionate and salmeterol)
• Albuterol Sulfate (albuterol sulfate inhalation solution)
• Proair Digihaler (albuterol sulfate inhalation powder)
• Albuterol Sulfate Tablets (albuterol sulfate tablets)
• Atrovent HFA (ipratropium bromide inhalation aerosol)
• Atrovent Nasal Spray (ipratropium bromide nasal spray)
• Atrovent Nasal Spray .06 (ipratropium bromide nasal spray .06)
• Azmacort (triamcinolone acetonide (inhalation aerosol))
• Bevespi Aerosphere (glycopyrrolate and formoterol fumarate inhalation aerosol)
• Pulmicort Turbuhaler (budesonide)
• Symbicort (budesonide and formoterol fumarate dihydrate)
• Pulmicort Flexhaler (budesonide inhalation powder)
• Pulmicort Respules (budesonide inhalation suspension)
• Dulera (mometasone furoate, formoterol fumarate dihydrate inhalation)
• Singulair (montelukast sodium)
• Xolair (omalizumab)
• Serevent Diskus (salmeterol xinafoate)